Main description:

This book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are:
Recent advances in ALS research
News about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects
Predictive, Preventive and Personalised Medicine in aging macular degeneration
Advances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection
Multiple sclerosis related biomarkers: perspectives for clinical application
Preventive clinical trials in brain aging: new trends & the need of guidelines
MCI_ clinical guidelines in early diagnosis of dementia
Alzheimer's disease: diagnostics, prognostics and the road to prevention
Biomarkers for early diagnosis of Parkinson's and Alzheimer's diseases
Synucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms

Contents:

Part I

1. What is this book series about? Foreword of Book Series Editor; O. Golubnitschaja

2. Preface; S. Mandel

3. Introductory chapter; S. Mandel and O. Golubnitschaja

Part II

4. Individual predispositions in healthy vasospastic individuals: Patient profiling for targeted prevention of "down-stream" pathologies as cost-effective personalised medicine; K. Yeghiazaryan, J. Flammer, O. Golubnitschaja

5. Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders; S. Fulda and M. Manconi

6. New animal models of progressive neurodegeneration: tools for developing predictive diagnostics and identifying presymptomatic therapeutic targets; A. L. Marriott, D. A. Gill, C. A. Shaw, R. A. Tasker

7. Tau pathology: A selected view on the current status; I. Gozes

Part III

8. The Use of Biomarkers for Prediction and Prevention of Alzheimer's and Parkinson's Diseases; S. A. Mandel & A. D. Korczyn

9. Making clinical trials of Alzheimer's disease delay-of-onset a reality by use of a prognostic genetic biomarker; Iris Grossman

10. An update on CSF biomarkers of Parkinson's disease; Peter LeWitt, B Russell Huber, Jing Zhang

Part IV

11. Glaucomatous optic neuropathy: Risk assessment and potential targets for effective prevention and treatments tailored to the patient; O. Golubnitschaja, K. Yeghiazaryan, J. Flammer

Part V

12. Toward a personalized approach in amyotrophic lateral sclerosis: new developments in diagnosis, genetics, pathogenesis and therapies; B. Nefussy & V. E. Drory

13. Recent advances in ALS research: perspectives for personalized clinical application; C. Benkler, D. Offen, E. Melamed, T. Amit, S. Mandel, M. B.H. Youdim, O. Weinreb

Part VI

14. Exercise in Multiple Sclerosis - an Integral Component of Disease Management; A. Doering, C. F. Pfueller, F. Pau, J. Doerr

15. Bridging the Informatics Gap between Bench and Bedside: Implications to Neurodegenerative Diseases; A. Shabo (Shvo) & M. Scarpa

Part VII

16. Personalized Medicine In Rare Paediatric Neurometabolic Diseases; R. Tomanin, C. M. Bellettato, F. D'Avanzo, A. Zanetti, A. Ceci, D. Begley, M. Scarpa